HCA Healthcare Inc. has emerged as a standout performer in the health care sector, with fourth-quarter results exceeding expectations and 2026 guidance signaling continued momentum.
The company's efficiency improvements and additional revenue from state-directed payment programs (SDPs) have positioned it favorably despite valuation concerns.
Analysts note that the guided EBITDA of $16 billion for 2026 surpasses market expectations of $15.6-15.7 billion, reflecting confidence in operational initiatives.
Medicaid SDPs, particularly Florida's potential approval, could contribute up to $1.4 billion in additional revenue. However, approval timelines remain uncertain.
ACA subsidy extensions, an aging population, and volume growth support HCA's long-term prospects. The stock trades at 10x EBITDA, but with a PEG ratio of 0.44, it may be undervalued relative to growth.
However, OPPS cuts around 2028 could pressure growth. Investors must weigh policy risks.
